APA (7th ed.) Citation

Tuncer, H. H., Ghosh, N., Fleury, I., Leslie, L. A., Manzoor, B. S., Lamanna, N., . . . Shadman, M. (2024). Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies. Clinical Lymphoma, Myeloma and Leukemia, 24(Supplement 1), S183. https://doi.org/10.1016/S2152-2650(24)00591-3

Chicago Style (17th ed.) Citation

Tuncer, Hande H., et al. "Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies." Clinical Lymphoma, Myeloma and Leukemia 24, no. Supplement 1 (2024): S183. https://doi.org/10.1016/S2152-2650(24)00591-3.

MLA (8th ed.) Citation

Tuncer, Hande H., et al. "Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies." Clinical Lymphoma, Myeloma and Leukemia, vol. 24, no. Supplement 1, 2024, p. S183, https://doi.org/10.1016/S2152-2650(24)00591-3.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.